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Abstract  
Background and Objective: Chemokine (C-C motif) ligand (CCL)2, the prototype Th2 chemokine, 
is secreted by tumor cells, and has growth promoting effects. Whether CCL2 protumorigenic 
activities will be validated, then CCL2 and its receptor CCR2 may be therapeutic targets in cancer. 
Methods: We tested in “primary human anaplastic thyroid carcinoma (ATC) cells” (ANA) versus 
“normal thyroid follicular cells” (TFC): a) CCL2 secretion basally, after IFN-γ and/or TNF-α stimulation; 
b) PPARγ activation by thiazolidinediones (TZDs), rosiglitazone or pioglitazone, on CCL2 secretion, and 
on proliferation and apoptosis in ANA.  
Results: ANA produced basally CCL2, at a higher level versus TFC. IFN-γ or TNF-α dose-dependently 
induced the CCL2 release in 3/6 or 5/6 ANA, respectively, but in all TFC. IFN-γ+TNF-α induced a 
synergistic release of CCL2 in all TFC, but only in 1/6 ATC. TZDs exerted an inhibition of CCL2 release 
in 3/6 ANA, while had no effect in TFC. Pioglitazone inhibition of ANA proliferation was not associated 
with the effect on CCL2; NF-κB and ERK1/2 were basally activated in ANA, increased by IFN-γ+TNF-
α, and pioglitazone inhibited IFN-γ+TNF-α activation. CCL2 serum levels were higher in 6 ATC patients 
than in 5 controls (813±345 versus 345±212, pg/mL; respectively; P<0.01, ANOVA). 
Conclusion: ANA produce CCL2 basally and after cytokines stimulation, with an extremely variable 
pattern of modulation, suggesting different types of deregulation in the chemokine modulation. Serum 
CCL2 is increased in ATC patients. Further studies will be necessary to evaluate if CCL2 might be used 
as a marker in the follow-up of ATC patients. 
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Introduction  
  
Chemokines and their receptors are expressed by tumor cells and by host cells, in primary tumors and in 
metastatic loci, and they may have different effects on tumorigenesis [1]. 
Little is known about chemokines in anaplastic thyroid carcinoma (ATC) [2].  
ATC is an endocrine malignancy, rare and rapidly fatal [3-7]. At present, the most effective drug for 
treating ATC is the multimodal treatment protocol that include surgery, chemotherapy (doxorubicin and 
cisplatin), and hyperfractionated accelerated external beam radiotherapy [8] (10 months median patient 
survival) [8]. Thus, the identification of an effective systemi                        c treatment for ATC would 
represent a considerable advance in the management of this fatal thyroid cancer [9]. Promising future 
directions include peroxisome proliferator-activated receptor-γ (PPARγ) agonists, aurora kinase inhibitors 
and tyrosine kinase inhibitors [10-12], gene therapy [13] and oncolytic virotherapy [14, 15]. 
In humans PPARγ is a type II nuclear receptor, encoded by the PPARg gene [16, 17] that, upon 
activation, binds to DNA in complex with the retinoid X nuclear receptor (RXR), increasing or decreasing 
the transcription of specific genes. PPARα, PPARδ, and PPARγ are the known three PPARs subtypes. 
PPARγ regulates glucose metabolism and fatty acid storage, stimulates lipid uptake and adipogenesis by 
fat cells, and is a regulator of adipocyte differentiation [18]. PPARγ is involved in the pathogenesis of 
different diseases: obesity, diabetes, atherosclerosis, and cancer. Its agonists are implicated in the 
treatment of hyperlipidaemia and hyperglycemia [19]. PPARγ decreases the inflammatory response of 
many cardiovascular cells, mainly endothelial cells [20], reduces atherosclerosis, activating the PON1 
gene, that increases the synthesis and release of paraoxonase 1 from the liver [21].  
PPARγ are involved in autoimmune disorders [22] and in carcinogenesis [23], too.  
In ATC, Hayashi et al. showed the expression of both PPARγ gene and protein in 5 human cell lines [24]; 
cell proliferation was reduced by PPARγ agonists inducing apoptosis. Moreover, PPARγ agonists 
decreased the invasive potential of the 5 ATC cell lines [24].  
Aiello et al. [25] studied the biologic effects of the PPARγ agonists ciglitazone (CGZ) and rosiglitazone 
(RGZ) in ATC cell lines, and demonstrated that RGZ increased the expression of thyroid-specific markers 
of differentiation. 
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Marlow et al. [26] showed that, the high-affinity PPARγ agonist RS5444, reactivating suppressed RhoB, 
induced the cyclin-dependent kinase inhibitor p21 and inhibited ATC cells proliferation.  
Antonelli et al. have shown that pioglitazone (PGZ) and RGZ can reduce cell growth and proliferation in 
human primary ATC cells, from different patients [27]. Moreover, in another in vitro study it was shown 
that the results of chemosensitivity tests with PPARγ agonists in primary ATC cells obtained directly 
from fine-needle aspiration are similar to those obtained from biopsies [28, 29].  
A recent paper showed that TZDs are able to modulate chemokine secretion also in ATC. In fact, ATC 
cells produced CXCL10 basally and after stimulation by cytokines, with an extremely variable pattern of 
modulation by TNF-α, IFN-γ or TZDs, suggesting for different types of dysregulation of the intracellular 
pathways involved in the chemokine modulation in ATC with respect to differentiated thyroid cancer 
(DTC) and control thyroid follicular cells (TFC) [30].  
More recently a phase I study [31] was conducted in 15 ATC patients, to evaluate the potential 
effectiveness of paclitaxel and efatutazone (EFA) at different doses (0.15 mg of EFA in 7 patients, 0.3 mg 
in 6 patients, and 0.5 mg in 2 patients). One subject, administered with 0.3 mg of EFA, had a PR; 7 
patients had SD. The median times to progression in patients treated with 0.15 mg and 0.3 mg of EFA, 
were 48 and 68 days, while the median survival were 98 versus 138 days, respectively. This study 
suggested that the combination between EFA and paclitaxel was safe and tolerated and had biologic 
activity [31]. 
Chemokine (C-C motif) ligand (CCL)2 (or monocyte chemoattractant protein-1) is the prototype T helper 
(Th)2 chemokine. CCL2 can be secreted by tumor cells, and it has growth promoting effects [32], shown 
in animal models and clinical epidemiological studies. In case that protumorigenic activities of CCL2 will 
be validated, then CCL2 and its receptor CCR2 may be therapeutic targets in cancer [32]. 
ATC is strongly infiltrated by immune cells, specifically macrophages [33], that seem to have a 
determinant role in ATC development and progression. Tumor-associated macrophages (TAMs) 
may differentiate from peripheral blood monocytes recruited in a CCL2-dependent manner [34]. 
Virus-infected cells activate an antiviral response in order to block viral replication, involving the 
production of type I and type III interferons (IFNs) and the modulation of cytokine and chemokine 
release. Viruses have developed different strategies to oppose cellular antiviral mechanisms, for 
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example  by modulating the activity of transcription factors involved in the production of 
chemokines and cytokines [35]. 
Recently, it has been shown that the oncolytic adenovirus dl922-947, evaluated for the treatment of 
ATC, reduces interleukin (IL)-8 and CCL2 secretion by the tumor cell lines 8505-c and BHT101-5 
through the displacement of NF-κB p65 from IL-8 and CCL2 promoters. Moreover, the dl922-947-
induced reduction of the secretion of IL-8 and CCL2 correlated with impaired tumor angiogenesis 
and decreased macrophage density in vitro and in vivo [15]. 
In this study we aimed to: a) evaluate CCL2 in ATC cells compared to normal TFC; b) test the effect of 
IFN-γ and/or tumor necrosis factor (TNF)-α influence on the secretion of the β-chemokine CCL2 in 
primary ATC cells, in comparison with TFC; c) test the effect of PPARγ activation on CCL2 secretion, 
and proliferation in these cell types; d) evaluate the pathways involved in the modulation of CCL2 by 
cytokines and PPARγ. 
 
Materials and Methods 
 
Patients source for thyroid tissue 
Thyroid tissues were collected from 8 ATC patients undergoing thyroidectomy, and normal thyroid 
tissues from 5 patients (2 during parathyroidectomy, and 3 during laryngeal intervention). The diagnosis 
was determined according to known laboratory, clinical and histological criteria [36, 37]. The absence of 
expression of thyroperoxidase (TPO), thyrotropin (TSH) receptor, sodium/iodide symporter (NIS), and 
thyroglobulin (Tg) was shown by immunohistochemistry. 
Microdissection and DNA extraction, detection of BRAF mutation by polymerase chain reaction single 
strand conformation polymorphism and direct DNA sequencing were performed as previously described 
[38]. Informed consent to the study was obtained from all study subjects, and was approved by the local 
ethical committee. 
ATC cell culture 
ATC cell cultures were established as previously described [29, 39, 40]. 
The absence of expression of TPO, TSH receptor, NIS and Tg, and a partial and focal positivity to 
cytokeratin were shown by immunocytochemistry.  
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Thyroid follicular cells 
Thyrocytes were prepared as previously described [36]. 
CCL2 secretion assay 
Cells were seeded (3000 cells) in 96-well plates in growth medium, that was removed after 24 h, and cells 
were then washed in phosphate buffered saline (PBS), and incubated in medium without serum and 
phenol red. Cells were treated with IFN-γ (500, 1000, 5000, 10000 IU/mL; R&D Systems, MN, USA) 
and 10 ng/mL TNF-α (R&D Systems), alone or in combination, for 24 h. The concentration of TNF-α 
was chosen according to the results obtained from preceding experiments to have the highest responses. 
The supernatant was then collected and kept frozen at –20°C until CCL2 assay. 
In order to test the modulation of IFN-γ-induced chemokine secretion exercised by PPARγ activators, 
cells were treated with IFN-γ (1000 IU/mL) and TNF-α (10 ng/mL) in the presence or absence of 
increasing concentrations (0, 1, 10, 20 mmol L-1) of the PPARγ agonists RGZ (Glaxo, UK), or PGZ 
(Alexis Biochemicals, Switzerland) for 24 h, and CCL2 was dosed in the supernatants by enzyme-linked 
immunosorbent assay (ELISA). The results are the mean for each sample, and the experiments were 
conducted in triplicate for each cell preparation. 
The PPARγ agonists concentrations were selected on the basis of their near therapy doses (5-10 mmol L-1 
for RGZ and PGZ) according to their pharmacokinetics (Cmax and area under the time-concentration 
curve, AUC) [27, 28]. 
Cell viability test 
After treatment with 10 or 20 mmol L-1 PGZ for 24 h, viable cells were evaluated by the viability and 
proliferation test “Cell Proliferation Reagent WST-1” (Roche, Mannheim, Germany) [27-29, 37]. 
The experiments were conducted in triplicate for each sample. The results are the mean for each sample. 
Proliferation assay: cell counting 
The proliferation was evaluated also using the cell number counting with a hemocytometer, after 
treatment with 10 or 20 mmol L-1 PGZ for 24 h [27-29, 37]. 
ELISA for CCL2 
CCL2 levels were assayed in culture supernatants, and in the serum of 6/8 of ATC patients and 5 controls, 
by a quantitative sandwich immunoassay using a commercially available kit (R&D Systems). The mean 
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minimum detectable dose was 4.6 pg/mL. The intra- and inter-assay coefficients of variation were 4.6% 
and 5.7%. 
Apoptosis determination- Hoechst uptake 
Primary ATC cell cultures (ANA) were seeded at a concentration of 35000 cells/mL in a 96-wells plate in 
a final volume of 100 mL/well, and treated with PGZ (10 or 20 mmol L-1) for 48 h, in a humidified 
atmosphere (37°C, 5% CO2), then stained with Hoechst 33342 [41-43]. 
It was calculated the apoptosis index (ratio between apoptotic and total cells x100), and the results were 
evaluated by analysis of variance (ANOVA) with Newman–Keuls multiple comparisons test. 
Apoptosis determination- Annexin V binding assay 
Cells were seeded in Lab-tekII Chamber Slide System (Nalge Nunc International, Naperville, IL, USA), 
treated with 10 or 20 mmol L-1 PGZ for 48 h, and processed as previously described [41-43]. 
Nuclear extracts preparation 
ANA and TFC cells were seeded at a concentration of 200000 cells/mL in cell culture dishes in 10 mL 
and treated with IFN-γ (1000 IU/mL) and TNF-α (10 ng/mL) in the presence or absence of 10 or 20 mmol 
L-1 PGZ for 1 h. 
Nuclear extracts (nucleosol) were obtained as previously described [41].  
Electrophoretic mobility shift assay (EMSA) 
DNA binding reactions and electrophoresis were performed as previously described [41]. 
Immunoblotting 
ANA cells were seeded at a concentration of 200000 cells/mL in cell culture dishes in 10 mL and treated 
with IFN-γ (1000 IU/mL) and TNF-α (10 ng/mL) in the presence or absence of 10 or 20 mmol L-1 PGZ 
for 24 h. 
At the end of the treatments, cells were processed as previously described [41, 44].  
Data analysis 
Values are given as mean±standard deviation (SD) for normally distributed variables (in text), or 
mean±standard error of mean (SEM) (in figures), otherwise as median and [interquartile range]. Mean 
group values were compared by using one-way ANOVA for normally distributed variables, otherwise by 
the Mann-Whitney U or Kruskal-Wallis test. Proportions were compared by the χ2 test. Post-hoc 
comparisons on normally distributed variables were carried out using the Bonferroni-Dunn test.  
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Results 
 
In vitro studies  
In ATC cells, CCL2 was detectable basally in supernatants in all samples, higher levels were observed in 
preparations B, C, D, F, G and H, whilst a slight basal secretion was shown in A and E (Figure 1). The 
basal level of CCL2 in ATC supernatants ranged from 104 to 16207 pg/mL, with a mean level of 6134 ± 
4973 pg/mL (P < 0.05, versus controls), showing a median increase with respect to the CCL2 level in 
TFC (Figure 2). 
CCL2 release was induced dose-dependently by IFN-γ, only in preparations A, E, F, and H while had no 
effect in the other preparations (ANOVA, P < 0.05, versus basal). 
TNF-α alone in ATC cells dose-dependently induced the CCL2 release in all the preparations with the 
exception of preparation A; the stronger effect was observed in B, C and G (ANOVA, P < 0.05, versus 
basal). 
The combination of TNF-α and IFN-γ had a significant synergistic effect on the CCL2 secretion (Figure 
1) in preparation A, and showed no effect in the others (ANOVA, P < 0.05, versus IFN-γ). 
Treating ATC cells with RGZ, in the presence of IFN-γ and TNF-α, CCL2 release was inhibited dose-
dependently (Figure 1) in preparations A, F and H (ANOVA, P  < 0.05, versus IFN-γ+TNF-α), while no 
significant effects were present in the others. 
Similarly, the treatment of ATC cells with PGZ, in the presence of IFN-γ and TNF-α, dose-dependently 
inhibited CCL2 release (Figure 1) in preparations A, B, F and H (ANOVA, P  < 0.05, versus IFN-
γ+TNF- α), while no significant effects were present in the others.  
CCL2 (251 ± 241 pg/mL) was detectable in the supernatants collected from primary thyrocyte cultures. 
IFN-γ dose-dependently induced the CCL2 release (CCL2: 255 ± 236, 521 ± 283, 967 ± 489, 1187 ± 563, 
1389 ± 652 pg/mL; respectively, with IFN-γ 0, 500, 1000, 5000, 10000 IU/mL; ANOVA, P < 0.001). 
TNF-α dose-dependently induced the CCL2 release (CCL2: 247 ± 243, 438 ± 289, 694 ± 354, 859 ± 496 
pg/mL; respectively, with TNF-α 0, 1, 5, 10 ng/mL; ANOVA, P  < 0.001). The combination of IFN-γ and 
TNF-α had a significant synergistic effect on the CCL2 secretion (ANOVA, P  < 0.0001) (Figure 2). The 
treatment of TFC with RGZ or PGZ, added at the time of IFN-γ and TNF-α stimulation, had no 
significant effect on the CCL2 release (Figure 2). 
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For comparison, we have reported mean CCL2 values in TFC (5 preparations) or in ANA (8 preparations) 
in Table 1.  
 
 
 
 
 
 
 
 
 
Table 1. Mean CCL2 values in supernatant of thyroid follicular cells (TFC; 5 preparations), 
or in anaplastic thyroid cancer cells (ANA; 8 preparations). 
 
 TFC 
 
CCL2 (pg/mL) 
 
P ANA 
 
CCL2 (pg/mL) 
P 
Basal 
 
251 ± 241  6134 ± 4973  
IFN-γ 1000 IU/mL 
 
967 ± 489 < 0.05* 7336 ± 5312 ns* 
TNF-α 10 ng/mL 
 
859 ± 496 < 0.05* 12956 ± 7148 < 0.05* 
INF-γ+TNF-α 
 
2975 ± 738 < 0.05^ 13044 ± 8061 ns^ 
INF-γ+TNF-α+Rosi 
 
3086 ± 127 ns° 11986 ± 6893 ns° 
INF-γ+TNF-α+Pio 
 
2957 ± 263 ns° 11547 ± 7124 ns° 
 
* = versus basal; ^ = versus INF-γ or TNF-α; ° = versus INF-γ+TNF-α 
 
 
The antiproliferative effect of PGZ was evidenced after a minimum of 24 h of incubation and increased 
with longer incubations, while no antiproliferative effects were reported with shorter treatment times (10 
and 18 h). The concentrations of thiazolidinedione (TZD; PGZ) required to obtain the IE 50 (50% 
inhibition of growth) were calculated after 2 days (48 h of incubation). A reduction of proliferation 
compared to the control was demonstrated by WST-1 assay in ANA cells (after 48 h of incubation with 
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PGZ) both at 1 h (Figure 3A) (from the start of tetrazolium reaction) [of 8% and 17% with PGZ 10 (P = 
ns) or 20 (P  < 0.01) mmol L-1], and at 2 h (Figure 3B) [of 10% and 24% with PGZ 10 (P  < 0.05) or 20 
(P  < 0.0001) mmol L-1] (P by ANOVA).  
The cell counting confirmed the above mentioned results (data not shown).   
The PGZ concentration necessary for IE 50 in ANA was 38 mmol L-1. 
Apoptosis index was obtained in ATC cells using the Hoechst method. The fluorescent Hoechst dye 
stained both control and cells treated with PGZ (10 and 20 mmol L-1 for 48 h). The percentage of 
apoptotic cells increased dose-dependently: 6% of the cells were apoptotic at the PGZ lower dose 
reaching more than 14% with PGZ 20 mmol L-1 (ANOVA, P < 0.001) (Figure 3C). The induced cell 
apoptosis was verified by Annexin V.  
In order to clarify the PPARγ agonists-inhibition on CCL2 secretion, the EMSA assay was conducted to 
evaluate the effect of TZD on nuclear factor-kB (NF-kB) activation in the ATC cells (Figure 4A). NF-kB 
was constitutively activated in ATC cells (lane 3) and its DNA binding activity was increased by the 
treatment with IFN-γ and TNF-α (lane 4). The NF-kB activation by IFN-γ and TNF-α was significantly 
reduced by PGZ (20 mmol L-1) alone (lane 2) or in combination with IFN-γ+TNF-α (lane 1) and also the 
treatment with 10 mmol L-1 PGZ inhibited the nuclear translocation of NF-kB (data not shown). NF-kB 
was not constitutively activated in TFC cells, while it was induced by IFN-γ+TNF-α, and inhibited by 
PGZ (data not shown). 
As regards mitogen-activated protein kinase (MAPK) extracellular-signal-regulated kinase 1/2 (ERK1/2), 
we demonstrated that ERK1/2 are activated at the basal level in ATC cells, and IFN-γ+TNF-α increased 
its activation. PGZ (20 mmol L-1) inhibited the cytokines-induced ERK1/2 phosphorylation (Figure 4B). 
Three ATC presented the V600EBRAF mutation. IFN-γ and/or TNF-α stimulated chemokines secretion, 
RGZ and/or PGZ modulated it, and PGZ inhibited cell proliferation similarly both in ATC from tumors 
with V600EBRAF mutation, and from tumors without BRAF mutations (data not shown). 
The proliferation of TFC cells was decreased slightly but not significantly by PGZ, while it had no effect 
on total protein content (data not shown).  
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In vivo studies 
CCL2 levels were measured in the serum of 6 ATC patients and 5 controls (813 ± 345 versus 345 ± 212, 
pg/mL; respectively), showing significantly increased levels in ATC patients (P < 0.01, by ANOVA). No 
relationship among CCL2 serum levels and the clinical presentations of the ATC patients was observed. 
 
Discussion 
 
Our results show that ANA produced basally CCL2, at a higher level compared to TFC. Furthermore, 
circulating CCL2 is increased in ATC patients. CCL2 chemokine is secreted by ATC cells, after the 
treatment with cytokines, with an extremely variable pattern of modulation (no effect, or inhibition, or 
stimulation) by TNF-α, IFN-γ or TZDs, and a variable strength of the induced effect. CCL2 was secreted 
basally by TFC, and responded to IFN-γ or TNF-α, alone or in combination, in agreement with the results 
obtained by previous studies [45-47]. However, the basal level of CCL2 in ATC supernatants was higher 
compared to the CCL2 level in TFC. If CCL2 may be a marker of aggressiveness remains to be 
established.  
IFN-γ dose-dependently induced the CCL2 release only in 4/8 ATC preparations, while all TFC 
responded to IFN-γ. So far, it appears that progressive dedifferentiation of thyroid cells seems to increase 
the levels of basal CCL2 secretion while reducing its sensitivity to cytokines stimuli; this apparent 
discrepancy remains to be clarified. 
TNF-α induced the CCL2 release in 7/8 ATC preparations, while the response was present in all TFC (in 
full agreement with the results obtained by other studies in TFC) [45-48].  
IFN-γ/TNF-α synergism on CCL2 secretion has been shown in TFC in our study, in agreement with the 
results of other papers [45-47]. However, IFN-γ+TNF-α had a significant synergistic effect on the CCL2 
secretion only in 1/8 ATC preparation, and showed no significant effect in the others. 
Several intracellular signaling pathways have been identified that mediate the cytokines-induced CCL2 
expression. Among them, NF-kB is a well-known transcription factor that mediates induction of CCL2 
release in various cell types, by: a) IFN-γ [49, 50]; b) TNF-α [51, 52]; c) or the combination of IFN-
γ+TNF-α [46, 47]. 
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In this study we demonstrate an increased NF-kB activation in ATC cells, after IFN-γ, or TNF-α, or IFN-
γ+TNF-α stimulation, and this apparently agrees with what observed in the above mentioned studies. 
However, probably other pathways are involved, too, as the NF-kB activation was present also in ATC 
preparations in which the IFN-γ, or TNF-α, or IFN-γ+TNF-α stimulatory effect on CCL2 was not 
observed.  
The involvement of ERK activation in CCL2 induction by TNF-α has been shown also by other studies 
[53, 54]. We demonstrate that ERK1/2 are basally activated in ATC cells, and IFN-γ+TNF-α stimulated 
phosphorylation and activation of ERK1/2. However, also in this case, a discrepancy between ERK 
activation and CCL2 secretion is observed, since the ERK activation was present also in ATC 
preparations in which the IFN-γ+TNF-α stimulatory effect was not observed, reinforcing the hypothesis 
that probably other pathways are involved in the induction of CCL2 secretion in ATC. 
PGZ exerted an inhibition of CCL2 release in preparations B, F and H, and a weak inhibitory effect in 
preparation A, while TZD had no effect in the other ATC, and in TFC. PPARγ activators have been 
shown to suppress CCL2 expression, via different pathways (MAPK phosphatase-1, Toll-like receptor) 
even in other cell types [55, 56]. 
As regards the mechanism of action involved in chemokine secretion, PPARγ agonists may act 
differently: 1) inhibiting NF-kB [57]; 2) increasing the phosphorylation and activation of ERK1/2 [58].  
NF-kB was activated in ATC cells at the basal level and TZDs inhibited its activation, as reported by 
Marx et al. [57]. Considering the MAPKinase ERK1/2, we have shown that PPARγ agonists were able to 
inhibit the cytokines-induced ERK1/2 phosphorylation [58]. Our data support TZDs effect on ATC 
proliferation, but are not in agreement with TZDs effects on CCL2 secretion, leading to hypothesize that 
other pathways take part in the chemokine modulation in ATC. 
Activation of PPARγ isoforms elicits both anti-neoplastic [59] and anti-inflammatory effects [36] in 
several types of mammalian cells. PPARγ are also expressed in human anaplastic cancer cell lines [24], 
and inhibited cell proliferation by inducing apoptosis [24]. Moreover, we have recently shown the 
antiproliferative effect of PPARγ agonists TZD in primary cultured human anaplastic and papillary 
dedifferentiated thyroid cancers cells [27, 28, 37]. 
Our study agrees that PPARγ agonists do not have an inhibitory effect in TFC, but report a significant 
antiproliferative effect in primary ATC cells. Of note, the modulation of IFN-γ-stimulated CCL2 
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secretion and the antiproliferative effect of PPARγ activators in ATC are not related. The discrepancy 
between TZDs effects on CCL2 secretion and the inhibitory role on ATC proliferation is presumably 
linked to the different involved pathways, as TZDs mediate growth inhibition inducing apoptosis, as 
previoulsy suggested by other studies [60].  
CCL2 was measured in the serum of 6 ATC patients and 5 controls, showing significantly increased 
levels in ATC patients. No relationship among CCL2 serum levels and the clinical presentations of the 
ATC patients was observed, possibly because of the limited number of tested samples. CCL2 is secreted 
by tumor cells, and it has growth promoting effects [32], reported in animal models and clinical 
epidemiological studies. CCL2 could promote tumor progression in two ways. CCL2 might be 
secreted by tumor cells, or tumor cells could stimulate its secretion by close stromal or endothelial 
cells [32]. CCL2 might exert its effects recruiting mononuclear cells, that could secrete growth or 
survival factors that would enhance tumor progression, or they could provide angiogenic factors as 
VEGF that could stimulate vessel formation and lead to tumor growth. On the other hand, CCL2 
could act in a paracrine or autocrine manner to promote tumor cell growth or survival. Whether 
protumorigenic activities of CCL2 will be validated, then CCL2 and its receptor CCR2 may be 
considered as therapeutic targets in cancer [32]. Further studies in larger numbers of ATC patients will 
be necessary to evaluate if CCL2 might be used as a marker in the follow-up of ATC patients.  
On the whole, the present results first show that ANA produced basally CCL2, at a higher level compared 
to TFC, and that circulating CCL2 is increased in ATC patients. ATC cells produce the CCL2 chemokine, 
basally and stimulated by cytokines, even if with an extremely variable pattern of modulation (no effect, 
or inhibition, or stimulation) by IFN-γ, TNF-α or TZDs, as the strength of the induced response. 
Furthermore, a discrepancy between the variable TZDs effect on CCL2 secretion and the inhibitory role 
on ATC proliferation has been evidenced. These different modulatory effects in various ATC 
preparations suggest different types of deregulation in the intracellular pathways involved in the 
chemokine modulation, as already described about the secretion of the CXCL10 chemokine in ATC cells 
in primary cultures [30]. However, this knowledge may help in discovering new targets for the treatments 
of ATC.  
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Figure Legends 
 
Figure 1 The effect of TNF-a, IFN-g, or of IFN-g+TNF-a, of rosiglitazone (Rosi; 20 mmol L-1; with IFN-
g+TNF-a), and of pioglitazone (Pio; 20 mmol L-1; with IFN-g+TNF-a) on CCL2 secretion is shown in 8 
different ATC cell preparations. Bars are mean ± SEM. * = P  < 0.05 or less versus control (Ctrl)  by 
Bonferroni-Dunn test; ** = P  < 0.05 or less versus IFN; *° = P  < 0.05 or less versus IFN+TNF. 
 
Figure 2 The effect of TNF-a, IFN-g, or of IFN-g+TNF-a, of rosiglitazone (Rosi; 20 mmol L-1; with IFN-
g+TNF-a), and of pioglitazone (Pio; 20 mmol L-1; with IFN-g+TNF-a) on CCL2 secretion is shown in 5 
different TFC preparations. The results are the mean of the 5 samples. Bars are mean ± SEM. * = P  < 
0.05 or less versus control (Ctrl) by Bonferroni-Dunn test; ** = P  < 0.05 or less versus IFN. 
 
Figure 3 (A) The results of WST-1 assay in ANA (after 48 h of incubation with pioglitazone - Pio) 
showed a reduction of proliferation with respect to the control both at 1 h (from the start of tetrazolium 
reaction) [of 8% and 17% with pioglitazone 10 (P = ns) or 20 (P  < 0.01) mmol L-1], and at 2 h (B) [of 
10% and 24% with pioglitazone 10 (P  < 0.05) or 20 (P  < 0.0001) mmol L-1] (P by ANOVA). (C) The 
percentage of apoptotic cells increased dose-dependently treating them with pioglitazone (Pio) 10 or 20 
mmol L-1 (ANOVA, P < 0.001). Bars are mean ± SEM. * = P  < 0.05 or less versus Control by 
Bonferroni-Dunn test. 
 
Figure 4 (A) NF-kB was constitutively activated in ATC cells (CTRL; lane 3) and its DNA binding 
activity increased with IFN-g and TNF-a (IFN+TNF; lane 4). Pioglitazone (PIO; 20 mmol L-1) alone (lane 
2) or combined with IFN-g and TNF-a (IFN+TNF+PIO; lane 1) significantly reduced the IFN-g and TNF-
a activation of NF-kB. (B) ERK1/2 are basally activated in ATC cells (Cont), IFN-g+TNF-a (TNF-INT) 
stimulated its activation. Pioglitazone (PIO; 20 mmol L-1) inhibited the cytokines-induced ERK1/2 
phosphorilation. 
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